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Abstract
The outcome of Genome-Wide Association Studies (GWAS) has challenged the field of blood pressure (BP) genetics as
previous candidate genes have not been among the top loci in these scans. We used Affymetrix 500K genotyping data of
KORA S3 cohort (n=1,644; Southern-Germany) to address (i) SNP coverage in 160 BP candidate genes; (ii) the evidence for
associations with BP traits in genome-wide and replication data, and haplotype analysis. In total, 160 gene regions (genic
region610 kb) covered 2,411 SNPs across 11.4 Mb. Marker densities in genes varied from 0 (n=11) to 0.6 SNPs/kb. On
average 52.5% of the HAPMAP SNPs per gene were captured. No evidence for association with BP was obtained for 1,449
tested SNPs. Considerable associations (P,10
23) were detected for the genes, where .50% of HAPMAP SNPs were tagged.
In general, genes with higher marker density (.0.2 SNPs/kb) revealed a better chance to reach close to significance
associations. Although, none of the detected P-values remained significant after Bonferroni correction (P,0.05/2319,
P,2.15610
25), the strength of some detected associations was close to this level: rs10889553 (LEPR) and systolic BP (SBP)
(P=4.5610
25) as well as rs10954174 (LEP) and diastolic BP (DBP) (P=5.20610
25). In total, 12 markers in 7 genes (ADRA2A,
LEP, LEPR, PTGER3, SLC2A1, SLC4A2, SLC8A1) revealed considerable association (P,10
23) either with SBP, DBP, and/or
hypertension (HYP). None of these were confirmed in replication samples (KORA S4, HYPEST, BRIGHT). However, supportive
evidence for the association of rs10889553 (LEPR) and rs11195419 (ADRA2A) with BP was obtained in meta-analysis across
samples stratified either by body mass index, smoking or alcohol consumption. Haplotype analysis highlighted LEPR and
PTGER3. In conclusion, the lack of associations in BP candidate genes may be attributed to inadequate marker coverage on
the genome-wide arrays, small phenotypic effects of the loci and/or complex interaction with life-style and metabolic
parameters.
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Hypertension is considered a multifactorial disease – it is
influenced by multiple genetic loci as well as environmental and
lifestyle factors including diet, smoking habits and physical
exercise. Despite the relatively high heritability (h
2 0.3–0.6) of
blood pressure [1], the identification of genetic factors contributing
to the variation in blood pressure levels and susceptibility to
hypertension in general population has remained challenging.
Majority of the currently available knowledge has been gained by
mapping the genes responsible for Mendelian forms of hyper- and
hypotension [2] and studying rodent models with various blood
pressure affecting phenotypes (e.g. Spontaneously hypertensive
rats) [3,4]. These studies have successfully pinpointed multiple
interacting molecular pathways that are involved in the determi-
nation of a subject’s blood pressure. Consequently, the genes
coding for the components of these molecular pathways have been
targets for the identification of common and rare genetic variation
affecting inter-individual differences in blood pressure levels
[2,5,6]. However, the results of a large number of association
studies conducted with blood pressure traits have been inconsis-
tent, suggesting a high locus and inter-population heterogeneity
and trait complexity. Also, differences in recruitment strategies
between the original and replication studies may affect the results
[7].
Genome wide association (GWA) based studies have emerged as
a novel alternative to explore simultaneously a large number of
genomic loci for associations with a phenotypic trait. This method
has shown great promise in ascertaining common polymorphisms
responsible for several complex phenotypes like diabetes, stroke
and coronary artery disease [8]. However, GWA studies with
blood pressure have not produced unequivocal results [7,9,10].
Disappointingly, the previously studied candidate genes have not
been among the top loci in these association scans. This outcome
of GWA studies has challenged several decades of research in the
field of blood pressure physiology and genetics that has produced a
large quantity of data implicating many genes in various aspects of
blood pressure regulation. One explanation may be that blood
pressure is determined by the combination of a large number of
gene variants, each contributing with a small effect, and thus the
conducted studies have been underpowered. Further possibility is
that blood pressure candidate genes have been insufficiently
tagged on the genotyping arrays [5,11,12].
We used Affymetrix 500K as model for a genome-wide
genotyping array and analyzed the genotyping data of 1,644
individuals from the Kooperative Gesundheitsforschung in der
Region Augsburg (KORA) S3 cohort originating from Southern-
Germany to study the following questions: (i) How are 160 genes
with prior evidence for involvement in blood pressure regulation
covered on the Affymetrix 500K array? (ii) Which candidate genes
show the strongest signal for association in an evidence-based
association study addressed by a genome-wide dataset? Are the
detected associations replicable in other study samples and meta-
analysis across samples? (iii) Does haplotype analysis improve the
results obtained for single markers?
Materials and Methods
Selection of candidate genes
The analysis focused on 160 candidate genes with prior
evidence of being involved in blood pressure regulation (Table
S1, Table S2). Majority of the genes were selected from
published literature reports on biology and genetics of blood
pressure. Selection criteria included genes responsible for the
Mendelian forms of hypertension or hypotension, location near
linkage peaks or quantitative trait loci (QTLs), reports on animal
models and human association studies etc. In addition to
literature, additional information was obtained from various
genome resources (OMIM, http://www.ncbi.nlm.nih.gov/sites/
entrez?db=omim; NCBI GeneBank and NCBI Locuslink http://
www.ncbi.nlm.nih.gov/; Ensembl http://www.ensembl.org/index.
html). Candidate gene list was also supplemented with loci involved
in other cardiovascular diseases related to hypertension (myocardial
infarction, coronary artery disease and stroke).
Studied genomic regions were defined to include the candidate
genes 610 kb of flanking sequence around each gene (defined
according to NCBI Build 35).
Ethics Statement
A detailed description of the recruitment and the applied
standardized examinations of the discovery sample KORA S3
(Kooperative Gesundheitsforschung in der Region Augsburg) and
replication samples KORA S4, HYPEST (HYPertension in
ESTonia) and BRIGHT (The MRC British Genetics of
Hypertension) has been described elsewhere [13,14,15]. All studies
have been approved by the local ethics committees and all
participants have given written informed consent.
Study subjects
All participants from KORA, HYPEST and BRIGHT studies
are of white European ancestry. The demographics of each study
sample is given in Table S3.
Briefly, KORA S3 and KORA S4 epidemiological cohorts
represent independent samples of unrelated subjects from the
general population from the Augsburg Area (Southern Germany)
recruited in 1994–1995 (S3) and 1999–2001 (S4) [14]. KORA
individuals (n=1,644) with data available for S3 and F3 (the
follow-up recruitment of S3 participants 10 years later, in 2003–
2004) surveys were selected for genome-wide genotyping.
HYPEST study sample consists of unrelated subjects (n=1,823)
recruited between 2004 and 2007 across Estonia with the aim to
identify hypertension risk factors in the Estonian population [15].
The recruited individuals have detailed epidemiological data and a
documented history of multiple systolic (SBP) and diastolic (DBP)
blood pressure measurements (on average 4.31 readings per
individual) during mean 3.17 years. The BRIGHT case-control
samples have been recruited across United Kingdom (UK)
(http://www.brightstudy.ac.uk)[13]. Cases originated from severe-
ly hypertensive families (1700 sib-pairs and 800 nuclear families)
and were defined as patients under antihypertensive treatment and
with BP readings $150/100 mmHg based on one reading or
$145/95 mmHg based on the mean of three readings. Healthy
normotensive controls (n=2000; blood pressure,140/90 mmHg,
no antihypertensive medication and no diagnosed diseases) were
recruited by matching age, sex and geographical distribution
across UK.
Genome-wide single-nucleotide polymorphism (SNP)
data and genotyping in replication experiments
Genome-wide SNP genotyping of 1,644 KORA S3 samples
was carried out in the framework of the KORA 500K
Consortium (http://epi.helmholtz-muenchen.de/kora-gen/seiten/
kora500k_e.php). Genotyping was performed using the Affyme-
trix Gene Chip Human Mapping 500K Array Set consisting
of two chips (Sty I and Nsp I) according to the manufacturer’s
instructions. The genotypes were determined using BRLMM
Blood Pressure Genes and GWAS
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of genotypes and genotyping quality control is described in
detail elsewhere (http://epi.gsf.de/kora-gen/seiten/kora500k_e.
php). SNPs with signals of unreliable genotyping quality (call
rate,93%) and deviation from Hardy-Weinberg Equilibrium
(HWE; p,0.001) were excluded from statistical analysis.
Replication genotyping of seven SNPs in KORA S4 samples
(n=1,830) was performed using the iPLEX assay (Sequenom).
After applying a call rate cutoff (93%) n=1765 individuals entered
the statistical analysis. Genotyping of two SNPs (rs10889553,
rs11195419) in the HYPEST and the BRIGHT samples was
performed using the KASPar chemistry, a competitive allele
specific PCR SNP genotyping system using FRET quencher
cassette oligos (Genotyping Unit of the William Harvey Research
Institute). Call rate was .97% for the HYPEST and .95% for
the BRIGHT samples. Both SNPs genotyped in replication stage
were in HWE.
Phenotypes in association analysis of Affymetrix 500K
SNPs in hypertension candidate genes and in replication
steps
Association analysis of Affymetrix 500K SNPs in hypertension
candidate genes was carried out using the KORA S3 500K
Consortium dataset (genotyped subjects: n=1,644; body mass
index, BMI=27.764.2 kg/m
2; age=55.667.0 years). Associa-
tion with systolic (SBP) and diastolic (DBP) blood pressure was
tested using only individuals, who were not receiving blood
pressure lowering medication (n=1,017). For case-control
analysis the groups of hypertensives (n=364) was defined as: (i)
individuals under antihypertensive medication; (ii) untreated
subjects with SBP$160 mmHg and/or DBP$100 (Grade 2
hypertension) mmHg or (iii) untreated individuals with
SBP$140 mmHg (Grade 1 hypertension) in S3 that developed
10 years later to Grade 2 or severe hypertension (F3 survey).
Control subjects (n=596) were selected to have optimal (,120/
80 mmHg) or normal (,130/85 mmHg) blood pressure mea-
sured during both S3 (original) and F3 (ten years later) surveys,
and had never been prescribed antihypertensive medication. For
replication we selected the individuals from KORA S4 survey
(n=1,830; BMI=25.662.7 kg/m
2; age=52.769.0 years) that
satisfied the same phenotype criteria as in GWAS with KORA
S3. A total of 1,551 subjects entered the association analysis with
SBP/DBP. Case-control association analysis (HYP) was per-
formed with 447 hypertensives/1,119 normotensives.
Further replication was performed with subjects from the
HYPEST (total n=1,823; BMI=26.263.9 kg/m
2;a g e =
45.4613.7 years) and BRIGHT (total n=4,370; BMI=
26.663.8 kg/m
2;a g e = 5 8 . 3 610.1 years) studies. Association
analysis with SBP and DBP was performed using 1,097
untreated HYPEST individuals. In HYPEST, the association
analysis with hypertension (HYP) was performed with cases
(n=596) defined as subjects with either BP readings$160/
100 mm Hg based on the median of several measurements or
receiving anti-hypertensive therapy. Controls (n=650; blood
pressure,130/85 mm Hg based on mean of two independent
readings across mean 3.17 years or,140/90 mm Hg based on
mean of $3 readings) were selected among the subjects that
have never been prescribed antihypertensive treatment. Case-
control association analysis (HYP) in the BRIGHT study was
performed with 2,401 hypertensives/1,969 normotensives. Since
BRIGHT cases (severe hypertension; all subjects treated with
anti-hypertensive medication) were collected as extremes, we
were unable to test associations with SBP and DBP.
Statistical methods
Testing for single marker associations was performed using
PLINK software (http://pngu.mgh.harvard.edu/,purcell/plink/)
[16] version 0.99q. Binary phenotype data was analysed using
Cochran-Armitage trend test (1 degree of freedom) and multivar-
iate analysis was performed using logistic regression with additive
disease model (age and sex of individuals were included as
covariates). SBP and DBP were tested using linear regression with
and without covariates (age, sex). No minor allele frequency limit
was set for the used markers and all markers that passed quality
control were tested for association.
The contribution of life-style factors to the association of genetic
markers with blood pressure was assessed by reanalyzing the study
samples stratified by: (i) body mass index, BMI [normal weight,
BMI,25 kg/m
2 (meta-analysis for SBP&DBP n=1,420, for
HYP n=2,532); overweight, BMI$25 kg/m
2 (meta-analysis for
SBP&DBP n=2,423, for HYP n=4,859)]; (ii) smoking habits [non-
smokers (meta-analysis for SBP&DBP n=1,558, for HYP
n=1,724); smokers, including smokers at the recruitment and ex-
smokers (meta-analysis for SBP&DBP n=1,708, for HYP
n=1,723)] and (iii) alcohol consumption [low consumers, ,20
g/day (meta-analysis for SBP&DBP n=2,054, for HYP n=2,222);
high consumers, $20 g/day (meta-analysis for SBP&DBP
n=1,205, for HYP n=1,218)]. For the BRIGHT study participants
the data for smoking and alcohol consumption was not available.
For analysing haplotype effects we used the WHAP version 2.09
software (http://pngu.mgh.harvard.edu/,purcell/whap/) [17],
which implicitly performs phasing and accounts for ambiguity in
haplotype inference. Regression based omnibus tests were
performed for all haplotypes with .1% frequencies at a given
locus. We used sliding window testing with corrections for multiple
testing within each studied region. Sliding window sizes of 1, 3, 5,
and 8 SNPs with a step size of 1 marker were used in our study.
600 permutations of data were performed for each window to
generate empirical P values. For detailed analysis and visualization
of results we used PHASE 2.1 software with default parameters to
generate estimated haplotypes for each individual in our sample
[18,19]. Haplotype effects to SBP were tested using two tailed
Mann-Whitney U test in R statistical package (http://www.
r-project.org/) [20] and haplotype effects to hypertension
phenotype were tested with logistic regression in PLINK. Haplo-
view 4.0 [21] was used to generate LD plots (http://www.broad.
mit.edu/mpg/haploview/index.php). Coverage was measured as
the percentage of SNPs (minor allele frequency, MAF$0.05) in
Hapmap phase II (release 23; CEU population) (http://www.
hapmap.org/) [22] localized in genic regions that were tagged on
the Affymetrix 500 k chip with r
2$0.8. The analysis included
SNPs on the Affymetrix array within 6200 kb from a gene and
passing quality control criteria in KORA 500K genotyping. Meta
analysis of studied populations was performed in R (meta package)
using inverse variance method with a fixed effect model. Power
calculations for linear regressions to SBP were performed in R
(pwr package). SBP distribution data from KORA S3 was used to
estimate f
2 values assuming additive genotype effects.
Results
Blood pressure candidate genes are unevenly covered
with SNPs on Affymetrix 500K array
The study was focused on Affymetrix 500K array SNPs tagging
genomic regions of 160 genes with prior evidence for the
involvement in blood pressure regulation (Table S1, Table
S2). In total, the genomic regions entering the analysis (genic
region 610 kb) covered 11.4 Mb and contained 2411 genotyped
Blood Pressure Genes and GWAS
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(n=1555; 64%), exonic (n=387; 16%) and flanking intergenic
regions (n=488; 20%). The analysis included also 21 non-
synonymous changes. In genotyped KORA S3 population, a
notable fraction of SNPs were either monomorphic (n=107;
4.4%) or rare (minor allele frequency, 0%,MAF,5%) variants
(n=464, 19.2%; Figure 1).
The length of the studied gene regions in Affymetrix 500K array
ranged from 0.8 kb (NPPC) to 645 kb (CACNA1C)( Table S1,
Table S2). The mean number of genotyped SNP-s/gene was 15.2
(range: 0–168) with the average intermarker distance 6.5 kb.
Marker densities varied from 0 to 0.6 markers/kb. A total of 11
(7%) short genes (#23 kb) did not contain any Affymetrix 500K
markers and had to be excluded from the analysis (ADRB3, AVP,
AVPR1B, GIPR, HP, INS, SLC5A2, SLC9A5, TBXA2R, TH and
VEGFB; Figure 2). Genes with higher marker density (.0.2
SNPs/kb) had a better chance to exhibit putative associations
(P,10
23) with tested blood pressure traits (Figure 2). The
strongest associations in genes with low marker density (n=74;
46% of genes; 0–0.16 SNPs/kb) did not reach P,10
23.
We further explored the representation of the HAPMAP SNPs
within blood pressure candidate genes on the Affymetrix 500K
array. On average 52.5% of the HAPMAP SNPs per gene were
captured (median coverage 59.5%) (Table S1, Table S2).
Putative associations with blood pressure traits (P,10
23) were
detected for the genes, where .50% of HAPMAP SNPs were
tagged. The one exception was ADRA2A (coverage 33.3%). For 71
genes (44.4%) Affymetrix 500K array captured only up to 50% of
the HAPMAP variants including 31 genes (19.4%) not tagged at
all. Overall we found that marker densities and coverage on the
Affymetrix 500K SNP-array are sufficient to test associations with
only half of the selected genes.
Single marker association analysis of GWA data
Affymetrix 500K genotype data for 2,304 polymorphic SNPs
located in 149 blood pressure candidate genes was derived from
the KORA S3 500K Consortium dataset (n=1,644).
Associations with hypertension (HYP) were tested by trend test
and logistic regression under additive genetic model adjusted by
age and sex as covariates. Associations with systolic (SBP) and
diastolic (DBP) blood pressure were assessed by linear regression.
More than half of the tested Affymetrix 500K markers (n=1449
markers; 63%) covering the majority of the candidate gene regions
(n=130; 81%) showed no evidence for association with blood
pressure (BP) in KORA S3 study sample (Table S2). Only 12
(0.50% of total tested) markers in 7 genes (ADRA2A, LEP, LEPR,
PTGER3, SLC2A1, SLC4A2, SLC8A1) revealed close to significance
associations (P,10
23) with at least one blood pressure trait
(Table 2). Additional 94 (4.1%) markers in 26 genes exhibited
suggestive associations with 0.01,P,0.001 (Table S1). The
strongest associations were detected between rs10954174 in Leptin
(LEP) gene and DBP (P=5.2610
25, linear regression); between
rs10889553 in Leptin receptor gene (LEPR) and SBP (P=4.5610
25,
linear regression) as well as hypertension (P=4.14610
24, logistic
regression). Although, none of the detected P values remained
significant after Bonferroni correction (P,0.05/2319, P,2.156
10
25), the strength of some of the detected associations was close
to this level. Power analysis revealed that the discovery cohort
KORA S3 was underpowered for the detection of associations
with markers with low minor allele frequency (MAF,0.1)
(Figure 3A) and/or small effect size (,3 mmHg for SBP)
(Figure 3B).
In three genes evidence for association with BP (P,10
23) was
detected with multiple markers: intronic SNPs in LEPR and
Sodium-Calcium Exchanger 1 (SLC8A1) were associated with SBP and
HYP; and markers localized in Alpha-2A-Adrenergic Receptor
(ADRA2A) intronless gene region were associated with DBP
(Table 2).
Replication of the initial associations and combined
analysis of the data
One SNP from each of the seven loci (ADRA2A, LEP, LEPR,
PTGER3, SLC2A1, SLC4A2, SLC8A1) revealing an association with
blood pressure traits in the KORA S3 discovery sample was
selected for replication. First replication was attempted using
KORA S4 sample (n=1,830), an independently recruited cohort
from the same population (Southern-Germany). None of the SNPs
entering replication retained their initial significance level of
P,10
23. Four SNPs (rs10889553, rs2303934, rs10954174,
rs11195419) were found to be marginally associated with BP
traits with P values,0.1 (Table S4). Two of these markers
(rs10889553 and rs11195419) with consistent effects in KORA S3
Figure 1. Histogram of minor allele frequencies of Affymetrix
500K markers (n=2411) located in blood pressure candidate
gene regions. Monomorphic markers (n=111) are indicated in light
gray colour.
doi:10.1371/journal.pone.0006034.g001
Table 1. Affymetrix 500K SNPs (n=2,411) in blood pressure
candidate genes by location and functional category.
Marker category No of markers
intronic 1555 (65%)
exonic 387 (16%)
untranslated regions 329 (85%)
coding regions 58 (15%)
non-synonymous 21 (36%)
synonymous 37 (64%)
intergenic 488 (19%)
doi:10.1371/journal.pone.0006034.t001
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(Estonian) cohort and in BRIGHT (UK) hypertensives-normoten-
sives case-control sample set. As in KORA S4, no statistically
significant association was detected between the studied SNPs in
replication samples HYPEST and BRIGHT (Table S4), as well
as in the meta-analysis combining the results of all replication
Figure 2. Coverage of blood pressure candidate genes (genic region 610 kb) with Affymetrix 500K chip SNP markers. Upper and
lower parts of the graph depict SNP density/kb and length of each analyzed gene region, respectively. Genes harboring the SNPs, which resulted in
strongest associations (P,10
23; detailed in Table 2) with hypertension (HYP), systolic (SBP) or diastolic (DBP) blood pressure in KORA S3 cohort are
highlighted in black.
doi:10.1371/journal.pone.0006034.g002
Table 2. The strongest associations (P,10
23) between blood pressure traits and Affymetrix 500K chip SNPs located in
hypertension candidate genes.
Gene Length
SNPs
Affy
on
Average
SNP SBP DBP Hypertension
Symbol Chr (bp)* 500K distance Top SNPs
Linear
regression
Linear
regression Trend test
Logistic
Regression
rs number MAF Location P-value (beta) P-value (beta) P-value P-value (OR)
ADRA2A 10 23649 4 5.9 kb rs11195419 10.6% 39 UTR 3.98610
22
(2.57)
6.56610
24
(2.56)
4.80610
22 1.52610
22 (1.50)
rs11195417 9.4% upstream 2.58610
22
(3.00)
8.31610
24
(2.71)
2.48610
22 7.61610
23 (2.68)
LEP 7 36350 16 2.3 kb rs10954174 0.1% 39 UTR 4.48610
22
(23.6)
5.20610
25
(28.6)
7.42610
22 1.00 (0.001)
LEPR 1 236502 49 4.8 kb rs10889553 5.4% intron 4.50610
25
(6.61)
3.16610
23
(2.90)
1.61610
24 4.14610
24
(2.16)
rs17097182 5.2% intron 6.68610
24
(5.62)
1.98610
22
(2.33)
7.13610
24 4.14610
23 (1.88)
PTGER3 1 215455 55 3.9 kb rs2268062 38.1% intron 4.27610
22
(21.51)
0.15 (20.65) 8.10610
24 7.21610
23
(22.69)
SLC2A1 1 52982 12 4.4 kb rs1105297 31.7% intron 0.58 (20.49) 8.27610
24
(21.67)
0.39 0.23 (21.20)
SLC4A2 7 36870 8 4.6 kb rs2303934 3.2% intron 0.24 (2.82) 0.36 (1.32) 5.66610
24 1.38610
23 (3.21)
SLC8A1 2 338158 123 2.7 kb rs405884 9.8% intron 2.27610
24
(24.82)
2.49610
22
(21.75)
3.90610
24 3.13610
24
(23.62)
rs406222 8.2% intron 1.48610
23
(24.15)
2.06610
23
(22.41)
6.62610
24 1.22610
23
(23.24)
rs394112 8.4% intron 1.48610
23
(24.18)
4.01610
23
(22.29)
8.43610
24 9.00610
24
(23.33)
rs415695 9.5% intron 1.86610
23
(23.86)
1.11610
22
(21.9)
1.66610
23 9.60610
24
(23.31)
*Length of the analyzed region includes genic region 610 kb. P-values,10
23 are indicated in bold. Hypertension – hypertensives/normotensives as cases and controls;
Chr – chromosome; MAF – minor allele frequency; OR – Odds Ratio.
doi:10.1371/journal.pone.0006034.t002
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Table 3). However, in the joint meta-analysis of the KORA S3
data and the replication samples the strength of the association
between rs10889553 (LEPR) and DBP was enhanced compared to
the original signal (discovery sample KORA S3, P=3.16610
23,
beta=2.79; Meta-analysis P=2.4610
23, beta=1.51).
Contribution lifestyle factors to genetic associations
Several metabolic and life-style parameters are known to affect
blood pressure in humans. We explored the effects of body mass
index (BMI), habits of smoking and alcohol consumption on the
associations between blood pressure and seven genetic markers
selected to the replication steps. We reanalyzed the discovery
sample KORA S3 and the data from replication steps by
subdividing individuals into normal weight (BMI,25 kg/m
2)
and overweight (BMI$25 kg/m
2) groups (Table 3). Similarly,
the study samples were stratified based on their (i) smoking habits
as non-smokers and smokers (including current and ex-smokers) as
well as (ii) alcohol consumption as low consumers (,20 g/day) or
high consumers ($20 g/day). After subdivision of study samples
based on BMI, the association of rs11195419 (ADRA2A) with
hypertension was detected only in the overweight group (KORA
S3: P=5.21610
22, OR=1.37; Replication: P=4.48610
22,
OR=1.17; Meta-analysis: P=8.0610
23, OR=1.20) and the
individuals with normal weight were not affected (P=0.78)
(Figure 4, Table 3). The same SNP was associated with
hypertension only among smokers (KORA S3: P=6.36
22,
OR=1.51; Replication: P=2.45610
22, OR=1.42; Meta-analy-
sis: P=3.66610
23, OR=1.45) and no effect was detected among
non-smokers (P=0.57).
In contrast, rs10889553 (LEPR) revealed association with
SBP (KORA S3: P=5.16610
22, beta=4.97; Replication: P=
7.05610
22, beta=2.26; Meta-analysis: P=9.80610
23, beta=
2.94;) and DBP (KORA S3: P=4.1610
21, beta=1.23; Replica-
tion: P=3.55610
22, beta=1.69; Meta-analysis: P=1.61610
22,
effect=1.71) only in the normal weight sub-group (Figure 4,
Table 3). This genetic marker showed also accumulating evidence
for the interaction with life-style factors. The association with
DBP and HYP was detected among smokers (meta-analysis for
DBP: P=9.63610
23, effect=1.45; meta-analysis for HYP:
P=1.31610
22, OR=1.46) and high alcohol consumers (meta-
analysis for DBP: P=7.66610
23, effect=2.25; meta-analysis for
HYP: P=2.98610
23, OR=1.67). Non-smokers and low-alcohol
consumers revealed no effect of the carrier status of rs10889553
genotype on their blood pressure (P.0.05). The remaining six
SNPs selected for the replication did not show consistent and
replicable interaction with studied life-style factors (Table S5,
Table S6, Table S7).
Haplotype analysis
We performed haplotype analysis for the seven genomic regions
(ADRA2A, LEP, LEPR, PTGER3, SLC2A1, SLC4A2, SLC8A1),
which revealed evidence for the association with blood pressure
traits using single-marker tests (P,10
23) in the initial KORA S3
sample (Table 1). Haplotype association with HYP, SBP and
DBP was tested using a regression-based method, which
simultaneously performs phasing and also accounts for ambiguity
in haplotype inference [17]. For each analysis based on the sliding
window approach the tested haplotype length was defined by the
number of neighboring SNPs forming a haplotype: one (for
comparison with single SNP tests), three, five and eight SNPs.
ADRA2A, LEP, SLC2A1, SLC4A2 and SLC8A1 loci displayed no
haplotype effects as the strongest P-values from regression-based
omnibus tests were obtained for window size=1 (Table 4,
Figure 5A). In two loci (PTGER3 and LEPR) the haplotype
analysis increased the strength of the associations. The best fitting
window size for the association of LEPR haplotypes with HYP and
SBP was five neighboring SNPs. For the PTGER3 gene the
strongest support was obtained for the association of three-marker
haplotypes with HYP. Both, in LEPR and in PTGER3 the region
revealing strongest association with blood pressure is located in the
59 part of the genes exhibiting moderate linkage disequilibrium
(LD) and covering first exons and introns (Figure 5B, C).
In order to test the susceptibility of each gene variant to blood
pressure determination, individual haplotypes of the 59 part of
LEPR and PTGER3 were determined by in silico phasing
(Figure 6). In the LEPR gene the haplotype TATCA
(rs1887285, rs17097182, rs10889553, rs970467, rs9436746) was
associated with hypertension (P=1.7610
24, OR=2.19; hyper-
tensives 8%; normotensives 4%) and higher SBP (P=2.8610
24,
Figure 3. Power analysis. Calculated statistical power at the Bonferroni significance level (a=2.15610
25) for the detection of SNP effects on SBP in
the discovery sample KORA S3 (untreated subjects, n=1,017). Power according to (A) alternative minor allele frequencies (MAF), shown for different
effect sizes (2, 3, 5 mmHg) and (B) effect sizes, shown for different MAFs (5%, 10%, 40%).
doi:10.1371/journal.pone.0006034.g003
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PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e6034Table 3. The associations of rs10889553 and rs11195419 with blood pressure in the discovery sample KORA S3, replication dataset
and meta-analysis: results for the full study sample and sub-samples stratified based on lifestyle factors.
Analysis cohort rs10889553 (LEPR) rs11195419 (ADRA2A)
group SBP DBP HYP SBP DBP HYP
All subjects KORA S3 P value 4.50610
25 3.16610
23 4.14610
24 3.98610
22 6.56610
24 9.32610
23
beta 6.43 2.79 0.75 2.83 2.62 0.41
95% CI 3.29; 9.57 0.89; 4.69 0.32; 1.17 0.47; 5.19 1.20; 4.04 0.10; 0.73
Replication
a P value 0.37 6.66610
22 0.43 0.53 0.59 0.12
beta 0.84 1.06 0.07 0.49 0.26 0.10
95% CI 21.00; 2.69 20.07; 2.20 20.11; 0.24 21.06; 2.04 20.69; 1.22 20.02; 0.22
KORA S3 and P value 5.60610
23 2.4610
23 4.52610
22 8.89610
22 1.39610
22 1.74610
22
replication
b beta 2.25 1.51 0.16 1.12 1.03 0.14
95% CI 0.66; 3.85 0.53; 2.49 0.00; 0.32 20.17; 2.42 0.20; 1.78 0.02; 0.25
Stratified by BMI:
BMI$25 kg/m
2 KORA S3 P value 6.41610
23 1.70610
22 1.89610
22 7.97610
23 1.57610
24 5.21610
22
beta 4.84 2.51 0.49 3.63 3.06 0.31
95% CI 1.37; 8.31 0.45; 4.57 0.08; 0.90 0.96; 6.31 1.48; 4.64 0.00; 0.63
Replication
a P value 0.41 0.96 0.48 0.13 0.34 4.48610
22
beta 21.04 0.04 0.07 1.59 0.60 0.16
95% CI 23.50; 1.42 21.42; 1.50 20.13; 0.28 20.46; 3.65 20.62; 1.81 0; 0.31
KORA S3 and P value 0.37 0.15 9.23610
22 6.90610
23 2.10610
23 8.00610
23
replication
b beta 0.92 0.87 0.16 2.44 1.51 0.18
95% CI 21.08; 2.93 20.32; 2.06 20.03; 0.34 0.67; 4.20 0.55; 2.47 0.05; 0.32
BMI,25 kg/m
2 KORA S3 P value 5.16610
22 0.41 0.29 0.43 0.44 0.77
beta 4.97 1.23 0.44 21.44 0.82 20.06
95% CI 20.02; 9.96 21.72; 4.17 20.40; 1.26 25.02; 2.14 21.27; 2.92 20.48; 0.35
Replication
a P value 7.05610
22 3.55610
22 0.94 0.25 0.45 0.94
beta 2.26 1.69 0.01 1.11 0.47 0.01
95% CI 20.19; 4.71 0.11; 3.26 20.34; 0.32 20.79; 3.02 20.77; 1.71 20.21; 0.23
KORA S3 and P value 9.80610
23 1.61610
22 0.96 7.71610
22 0.30 0.78
replication
b beta 2.94 1.71 0.01 1.60 0.56 0.03
95% CI 0.71; 5.17 0.32; 3.11 20.34; 0.37 20.17; 3.38 20.50; 1.63 20.18; 0.24
Stratified by smoking
c:
Smokers at the KORA S3 P value 1.32610
22 3.40610
22 0.13 7.78610
22 9.16610
24 6.36610
22
recruitment and/or beta 5.58 2.99 0.46 2.95 3.45 0.41
previous regular 95% CI 1.18; 9.98 0.23; 5.74 20.14; 1.06 20.32; 6.21 1.42; 5.47 20.02; 0.85
smoking periods Replication
a P value 0.48 7.94610
22 4.58610
22 0.45 0.28 2.45610
22
beta 0.97 1.45 0.36 0.84 0.74 0.35
95% CI 21.69; 3.62 20.17; 3.07 0.01; 0.71 21.35; 3.04 20.6; 2.08 0.04; 0.65
KORA S3 and P value 5.81610
22 9.63610
23 1.31610
22 0.11 6.03610
23 3.66610
23
replication
b beta 2.20 1.84 0.38 1.50 1.57 0.37
95% CI 20.08; 4.47 0.45; 3.24 0.08; 0.68 20.32; 3.32 0.45; 2.68 0.12; 0.62
nonsmokers KORA S3 P value 1.07610
23 4.44610
22 8.78610
24 0.19 9.32610
22 8.47610
22
beta 7.59 2.72 1.05 2.25 1.69 0.40
95% CI 3.07; 12.11 0.07; 5.37 0.43; 1.68 21.14; 5.64 20.28; 3.65 20.05; 0.85
Replication
a P value 0.83 0.95 0.26 0.20 0.56 0.68
beta 20.34 0.07 0.19 1.59 0.42 20.06
95% CI 23.53; 2.85 21.81; 1.94 20.14; 0.53 20.83; 4.01 21.00; 1.85 20.34; 0.22
KORA S3 and P value 0.08 0.22 1.02610
22 7.15610
22 0.14 0.57
replication
b beta 2.29 0.95 0.39 1.81 0.86 0.07
95% CI 20.31; 4.9 20.58; 2.48 0.09; 0.68 20.16; 3.78 20.29; 2.01 20.17; 0.31
Stratified by alcohol intake
c:
high alcohol KORA S3 P value 9.81610
24 1.59610
22 2.43610
23 3.87610
23 3.49610
23 2.23610
22
Blood Pressure Genes and GWAS
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e6034Mann-Whitney test) (Figure 6A). In contrast, the CTCCC variant
was associated with lower SBP (P=0.016) and was more frequent
in normotensives (P=0.064). Interestingly, the most common
PTGER3 haplotype ATAAA (rs2206344, rs3765894, SNP_A-
4228934, rs2744918, rs2268062) was associated with the risk for
hypertension (P=1.6610
25, OR=1.50; hypertensives 57%;
normotensives 46%), whereas two other prevalent variants exhibit
a protective effect (Figure 6B).
Discussion
In recent years genotyping technologies designed for genome-
wide association (GWA) studies have started to offer simultaneous
genotyping of large numbers of markers across many genes or
genomic regions [23]. We utilized a subset of information from a
genome wide genotyping dataset to address specifically the regions
in the genome that have been previously identified to be involved
in blood pressure (BP) regulation. The candidate gene targeted
analysis allowed the combination of cost effectiveness with a
hypothesis-based approach. In agreement with the fact that almost
half of the BP candidate genes (46%) were insufficiently covered
on the Affymetrix 500 k chip, we observed no associations in 126
(79%) of the studied genes. For many genes this result may indeed
reflect the lack of contribution of these SNP markers to the
susceptibility of hypertension and BP levels in the general
population from Germany. However, there is no basis to
generalize this across all populations as several susceptibility
variants for hypertension have been shown to exhibit geographic
region or population-specific associations. The lack of associations
in a large proportion of genes can also be attributed to inadequate
marker coverage on the Affymetrix 500 k chip. This may also have
affected the low representation of the BP loci with prior functional
evidence among the top results in previous GWA studies.
We explored the landscape of the genetic associations of the
Affymetrix 500 k markers covering BP genes from several angles:
single marker analysis followed by replication and meta-analysis,
single-marker analysis of the study samples stratified by life-style
factors (BMI, smoking and alcohol consumption), as well as
haplotype analysis across top loci. In single marker analysis only
0.50% of the tested SNPs reached considerable association
(P,10
23) with BP traits. The top SNPs were replicated in joint
analysis of the discovery sample and replication resources.
Interestingly, the two top SNPs of this study, rs11195419
(ADRA2A) and rs10889553 (LEPR) appeared to be consistently
associated with BP traits in study samples stratified based on the
body mass index (BMI) or life-style habits of the participants.
rs11195419 (ADRA2A) revealed contribution to BP levels among
overweight (BMI $25 kg/m
2) subjects and smokers, whereas
rs10889553 (LEPR) was associated with BP determination among
normal weight population (BMI,25 kg/m
2), smokers and high-
alcohol consumers. This indicates that one should be careful in
drawing conclusions about the contribution of the genetic
variation in BP candidate genes based on GWA results of single
studies. The variation of the study locus may not be well captured,
the true effect of the particular polymorphism may be small and
thus, may require a large sample size to be detected. Alternatively,
the association with blood pressure traits may depend on other
interacting factors such as BMI, smoking and alcohol consumption
habits, age, health status etc. The challenge to identify blood
pressure associations was further highlighted by power analysis.
The discovery sample KORA S3 was sufficiently powered to
identify associated markers with strong allelic effects ($4 mmHg)
Analysis cohort rs10889553 (LEPR) rs11195419 (ADRA2A)
group SBP DBP HYP SBP DBP HYP
consumption beta 8.91 4.18 1.17 5.92 3.82 0.60
($20 g/day) 95% CI 3.66; 14.17 0.80; 7.56 0.41; 1.92 1.93; 9.91 1.27; 6.36 0.09; 1.11
Replication
a P value 0.31 8.94610
22 7.05610
22 0.24 0.22 0.47
beta 1.62 1.64 0.35 1.51 0.96 0.13
95% CI 21.5; 4.74 20.25; 3.54 20.03; 0.72 21.03; 4.05 20.58; 2.51 20.22; 0.48
KORA S3 and P value 1.00610
22 7.66610
23 2.98610
23 1.09610
22 1.01610
22 0.06
replication
b beta 3.53 2.25 0.51 2.79 1.74 0.28
95% CI 0.84; 6.21 0.60; 3.90 0.17; 0.85 0.64; 4.93 0.41; 3.06 20.01; 0.57
low alcohol KORA S3 P value 1.11610
22 7.84610
22 5.28610
22 0.41 1.34610
22 0.10
consumption beta 5.08 2.08 0.53 1.22 2.15 0.34
(,20 g/day) 95% CI 1.17; 8.98 20.23; 4.39 20.01; 1.06 21.68; 4.12 0.45; 3.85 20.07; 0.74
Replication
a P value 0.85 0.66 0.14 0.47 0.54 0.32
beta 20.25 0.36 0.24 0.78 0.39 0.13
95% CI 22.94; 2.44 21.24; 1.97 20.08; 0.56 21.31; 2.86 20.85; 1.63 20.13; 0.39
KORA S3 and P value 0.20 0.17 2.32610
22 0.28 5.03610
22 8.65610
22
replication
b beta 1.46 0.92 0.32 0.93 1.00 0.19
95% CI 20.75; 3.68 20.4; 2.24 0.04; 0.59 20.76; 2.62 0.00; 2.00 20.03; 0.41
Associations were assessed using logistic (HYP) and linear (SBP, DBP) regressions under additive model with age and sex as covariates. Meta-analysis was performed
using inverse variance method with fixed effect model. Beta – effect size; CI, confidence interval.
ameta-analysis of replication samples: KORA S4, HYPEST for SBP and DBP (n=2,621); KORA S4, HYPEST, BRIGHT for HYP (n=6,593).
bmeta-analysis: KORA S3, KORA S4, HYPEST for SBP and DBP (n=3,638); KORA S3, KORA S4, HYPEST, BRIGHT for HYP (n=7,553).
cfor the BRIGHT study participants the data of smoking habits and alcohol consumption was not available.
doi:10.1371/journal.pone.0006034.t003
Table 3. Cont.
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e6034Figure 4. SNP effects in meta-analysis. Forest plots showing the effect sizes of the association of rs10889553 and rs11195419 with blood
pressure in subjects stratified according to their Body Mass Index, BMI (,25 kg/m
2 normal weight; $25 kg/m
2 overweight) and smoking habits.
Effects in individual populations KORA S3, KORA S4, HYPEST and BRIGHT are indicated by solid rectangles with sizes proportional to 95% confidence
interval (horizontal lines). Solid diamonds represent 95% confidence intervals in meta-analysis using inverse variance method with fixed effects.
Effects of association of (A) rs10889553 (Leptin receptor, LEPR) with systolic (SBP) and diastolic (DBP) blood pressure in normal weight population; (B)
rs11195419 (Alpha-2A-Adrenergic Receptor, ADRA2A) in with hypertension (HYP) and SBP in overweight population; (C) rs10889553 with DBP and
rs11195419 with HYP among smokers, including smokers at the recruitment and/or previous regular smokers during their lifetime.
doi:10.1371/journal.pone.0006034.g004
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Retrospective power calculations indicated that the detection of
the two top associations in LEPR (rs10889553; MAF=5.4%; effect
on SBP in meta-analysis: 2.25 mmHg) and ADRA2A (rs11195419;
MAF=10.6%; effect on SBP in meta-analysis: 1.12 mmHg) at the
Bonferroni significance level would have required sample sizes of
7,500 and 15,000–16,000 of the discovery sample, respectively.
Even though most of the markers in this study did not gain
statistical support for the contribution to the BP traits, some of the
most interesting associations are warrant further consideration. In
the initial evidence based association study with KORA S3 two of
the strongest associations were identified with markers in leptin
(LEP; 7q32.1) and leptin receptor (LEPR; 1p31.3) genes, components
of a single regulatory pathway. However, the study lacked the
power to attempt replication of rs10954174 in leptin as its minor
allele frequency is only 0.1%. In literature, another rare LEP SNP
located ,1.7 kb downstream from rs10954174 in the 39 UTR has
been associated with pulse pressure [24]. The support for the
association of LEPR with blood pressure was obtained by several
alternative approaches: in the discovery sample with all three BP
traits (P#3.16610
23), in meta-analysis across all cohort samples,
in haplotype analysis and in life-style stratified subgroup analysis.
rs10889553 is located in the second intron of the LEPR gene,
upstream of the coding region starting with exon 3. Previously,
exonic polymorphisms in LEPR have been associated with
hypertension in obesity [25,26]. It has been shown that the first
introns may contain regulatory elements and may be involved in
transcriptional regulation [27]. For example, a GWAS for fat mass
and obesity identified the strongest association in the first intron of
FTO gene [28]. Although initially the LEPR gene and its variants
have been implicated in the determination of body mass and
related phenotypes [29], there is growing evidence about the wider
role of LEPR in human metabolism. Recent studies have
associated LEPR gene variants with inflammatory traits like
plasma fibrinogen and C-reactive protein levels [30], bone density
[31,32] and insulin resistance in nondiabetic obese patients [33].
The second top SNP (rs11195419) highlighted in this study is
located within 39 UTR of Alpha-2A-Adrenergic Receptor (ADRA2A;
10q25.2) and was associated with blood pressure and hypertension
in overweight individuals (BMI$25 kg/m
2) and among smokers.
ADRA2A mediates stress responses and cardiac regulation via the
sympathetic nervous system and is also involved in the inhibition
of fatty acid mobilization from adipose tissue [34]. Consistently
with our results, a DraI RFLP in the 39 UTR of ADRA2A and an
upstream polymorphism C-1291G have been associated with
adiposity and abdominal obesity [34,35], as well as with increased
hypertension prevalence [36–38].
Our results suggest that environmental and life-style factors may
influence the penetrance of genetic risk factors for hypertension.
For example, inherited risk alleles for high blood pressure in the
LEPR gene affect the onset of hypertension predominantly in
individuals with unhealthy life-style. The results of this study may
also have implications for anti-hypertensive therapy. As the gene
ADRA2A codes for one of the targets for alpha adrenoreceptor
antagonists (also called alpha-blockers), the response to the
treatment may depend on carrier status of the identified gene
variants in conjunction with smoking habits.
Haplotype analysis may identify susceptibility loci that are not
captured by single marker tests and/or reveal the combinatory
effect of loci [23]. We identified haplotypes of LEPR, but also
PTGER3 gene, which were associated with increased risk for
hypertension in KORA S3 study population. PTGER3 is coding
for the receptor for prostaglandin E2, which may be involved in a
variety of functions including modulation of neurotransmitter
release in central and peripheral neurons and inhibition of sodium
and water reabsorption in kidney tubulus [39]. To our knowledge,
no studies have been conducted so far targeting the contribution of
PTGER3 gene variants to the determination of blood pressure.
In summary, using genome-wide genotyping array for targeting
candidate genes for a complex disease needs prior knowledge of
the SNP coverage on the genotyping array of choice. In some
genomic regions with sufficient LD, imputation could be one way
to overcome the low SNP density [40]. However, the major
limiting factor in blood pressure association studies appears to be
the small phenotypic effect of causal loci and complex interaction
with life-style, general health-status and age-associated metabolic
parameters. Even though in this study two genes, LEPR and
ADRA2A appeared to display supportive evidence for association
Table 4. P-values of gene haplotype association tests using sliding window analysis and alternative haplotype lengths.
GENE (no of SNPs)
Phenotype WS
* ADRA2A (4) LEP (16) LEPR (49) PTGER3 (55) SLC2A1 (12) SLC4A2 (8) SLC8A1 (123)
Hypertension 1 3.49610
22 0.103 1.83610
22 3.16610
22 0.582 9.98610
23 1.83610
22
3 0.565 0.241 2.00610
22 3.33610
23 0.188 3.83610
22 2.83610
22
5n a 0 . 1 8 3 8.32610
23 4.99610
23 0.436 0.135 5.32610
22
8 na 0.163 6.16610
22 9.98610
23 0.466 0.233 0.141
SBP 1 0.241 0.463 6.66610
23 0.429 0.611 0.369 1.50610
22
3 0.296 0.587 1.33610
22 0.195 0.195 0.351 4.33610
22
5n a 0 . 7 0 7 1.66610
23 0.331 0.281 0.419 5.66610
22
8 na 0.606 3.33610
23 0.366 0.278 0.381 8.65610
22
DBP 1 4.99610
23 0.749 0.121 0.215 1.83610
22 0.642 7.99610
22
3 9.98610
23 0.710 0.363 0.215 3.66610
22 0.682 0.271
5 na 0.501 0.141 0.253 6.49610
22 0.634 0.423
8n a 8.65610
22 0.226 0.225 0.161 0.474 0.103
Analysis was conducted for the hypertension candidate genes revealing strongest single marker associations with hypertension, systolic (SBP) or diastolic (DBP) blood
pressure. The lowest P values obtained for each gene are indicated in bold.
*Sliding window size - number of neighboring SNPs in the sliding window; na – not applicable.
doi:10.1371/journal.pone.0006034.t004
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are required to draw clear conclusions about their contribution to
the determination of blood pressure.
Supporting Information
Table S1 List of markers with association test p values,10
22.
a Coordinates include genic region 610 kb. Coordinates refer to
human genome build 35;
b% of SNPs (MAF$0.05) in Hapmap
phase II (CEU population) localized in genic regions that were
tagged on the Affymetrix 500 k chip with r
2$0.8. The analysis
included SNPs on the Affimetrix array within 6200 kb from a
gene and passing quality control criteria in the KORA 500K
genotyping.
cSBP - Systolic Blood pressure; DBP - Diastolic blood
pressure; Hypertension - Hypertension case-control;
dStatistical
tests were performed with plink software.
Found at: doi:10.1371/journal.pone.0006034.s001 (0.04 MBXLS)
Table S2 List of candidate regions with no significant associa-
tions.
aCoordinates include genic region 610 kb. Coordinates
refer to human genome build 35;
b% of SNPs (MAF$0.05) in
Hapmap phase II (CEU population) localized in genic regions that
were tagged on the Affymetrix 500 k chip with r
2$0.8. The
analysis included SNPs on the Affimetrix array within 6200 kb
from a gene and passing quality control criteria in the KORA
500K genotyping.
Found at: doi:10.1371/journal.pone.0006034.s002 (0.09 MB
XLS)
Figure 5. Results of haplotype association analysis with hypertension, SBP and DBP (detailed in Table 4). The upper part of each figure
shows the exon-intron structure of the analyzed candidate gene along with the distribution of Affymetrix 500K SNPs in the locus. The middle and the
lower part of the figures represent plotted P-values from the haplotype association tests under sliding window analysis (WHAP 2.09 software) and LD
structure (R
2) in KORA S3 study population, respectively. (A) Alpha-2A-Adrenergic Receptor (ADRA2A; sliding window=1 marker); (B) Leptin receptor
(LEPR, sliding window=5 markers); (C) Prostaglandin E Receptor (PTGER3, sliding window=3 markers).
doi:10.1371/journal.pone.0006034.g005
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Found at: doi:10.1371/journal.pone.0006034.s003 (0.01 MB
XLS)
Table S4 Association results with SNPs entering replication in
KORA S4. Results of regression analyses with age and sex as
covariates.
Found at: doi:10.1371/journal.pone.0006034.s004 (0.01 MB
XLS)
Table S5 Association results with SNPs entering replication
performed in study samples stratified according to BMI of the
participants. Results of regression analyses with age and sex as
covariates. Meta analysis over indicated populations was per-
formed using inverse variance method with a fixed effect model
Found at: doi:10.1371/journal.pone.0006034.s005 (0.02 MB
XLS)
Table S6 Association results with SNPs entering replication
performed in study samples stratified according to smoking habits
of the participants. Results of regression analyses with age and sex
as covariates. Meta analysis over indicated populations was
performed using inverse variance method with a fixed effect
model. Non-smokers - never smoked. Smokers - smokers at the
recruitment and/or previously during lifetime.
Found at: doi:10.1371/journal.pone.0006034.s006 (0.02 MB
XLS)
Table S7 Association results with SNPs entering replication
performed in study samples stratified according to alcohol
consumption habits of the participants. Results of regression
analyses with age and sex as covariates. Meta analysis over
indicated populations was performed using inverse variance
method with a fixed effect model.
Found at: doi:10.1371/journal.pone.0006034.s007 (0.02 MB
XLS)
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